These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17367541)

  • 1. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.
    Klenke FM; Abdollahi A; Bertl E; Gebhard MM; Ewerbeck V; Huber PE; Sckell A
    BMC Cancer; 2007 Mar; 7():49. PubMed ID: 17367541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice.
    Klenke FM; Gebhard MM; Ewerbeck V; Abdollahi A; Huber PE; Sckell A
    BMC Cancer; 2006 Jan; 6():9. PubMed ID: 16409625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined antiangiogenic and immune therapy of prostate cancer.
    Huang X; Raskovalova T; Lokshin A; Krasinskas A; Devlin J; Watkins S; Wolf SF; Gorelik E
    Angiogenesis; 2005; 8(1):13-23. PubMed ID: 16132614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
    Laird AD; Christensen JG; Li G; Carver J; Smith K; Xin X; Moss KG; Louie SG; Mendel DB; Cherrington JM
    FASEB J; 2002 May; 16(7):681-90. PubMed ID: 11978732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice].
    Jiang XT; Tao HQ; Zou SC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jul; 9(4):335-7. PubMed ID: 16886118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
    Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells.
    Nakamura T; Ozawa S; Kitagawa Y; Ueda M; Kubota T; Kitajima M
    Oncol Rep; 2006 Jan; 15(1):79-83. PubMed ID: 16328037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of Endostatin and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice].
    Zeng QL; Chu ZH; Zhou K; Luo XJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):376-8. PubMed ID: 18636363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
    Farhadi MR; Capelle HH; Erber R; Ullrich A; Vajkoczy P
    J Neurosurg; 2005 Feb; 102(2):363-70. PubMed ID: 15739567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
    Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
    Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival.
    Takamoto T; Sasaki M; Kuno T; Tamaki N
    Kobe J Med Sci; 2001 Aug; 47(4):181-91. PubMed ID: 11733657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis.
    Yorozuya K; Kubota T; Watanabe M; Hasegawa H; Ozawa S; Kitajima M; Chikahisa LM; Yamada Y
    Oncol Rep; 2005 Sep; 14(3):677-82. PubMed ID: 16077974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
    Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
    Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium.
    Lu B; Geng L; Musiek A; Tan J; Cao C; Donnelly E; McMahon G; Choy H; Hallahan DE
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):844-50. PubMed ID: 14967441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SU6668, a multitargeted angiogenesis inhibitor.
    Hoekman K
    Cancer J; 2001; 7 Suppl 3():S134-8. PubMed ID: 11779084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary tumor size-dependent inhibition of angiogenesis at a secondary site: an intravital microscopic study in mice.
    Sckell A; Safabakhsh N; Dellian M; Jain RK
    Cancer Res; 1998 Dec; 58(24):5866-9. PubMed ID: 9865747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68).
    Machida S; Saga Y; Takei Y; Mizuno I; Takayama T; Kohno T; Konno R; Ohwada M; Suzuki M
    Int J Cancer; 2005 Mar; 114(2):224-9. PubMed ID: 15551349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization.
    Keskin U; Totan Y; Karadağ R; Erdurmuş M; Aydın B
    Ophthalmic Res; 2012; 47(1):13-8. PubMed ID: 21691137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.